Prediction of response to trasutuzumab/pertuzumab/taxane therapy by microRNA in HER2 positive advanced breast cancer

被引：0
|
作者：
Kawachi, A. [1 ]
Shimomura, A. [1 ]
Matsuzaki, J. [2 ]
Kawauchi, J. [2 ]
Takizawa, S. [2 ]
Sakamoto, H. [3 ]
Shimizu, C. [1 ]
Tamura, K. [1 ]
Ochiya, T. [2 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Natl Canc Ctr, Res Inst, Div Mol & Cellular Med, Tokyo, Japan
[3] Natl Canc Ctr, Res Inst, FIOC, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
123P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pertuzumab as Part of Triple Therapy in HER-2 Positive Metastatic Breast Cancer
    Eslamian, G.
    AlHilali, M. N.
    Hameed, K.
    CLINICAL ONCOLOGY, 2018, 30 (06) : E43 - E43
  • [42] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Stanowicka-Grada, Malwina
    Senkus, Elzbieta
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (11) : 1633 - 1650
  • [43] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Malwina Stanowicka-Grada
    Elżbieta Senkus
    Current Treatment Options in Oncology, 2023, 24 : 1633 - 1650
  • [44] Differential response of HER2 positive breast cancer based on HER2 protein expression level
    Atallah, N. M.
    Toss, M. S.
    Al Saleem, M.
    Green, A. R.
    Mongan, N. P.
    Rakha, E. A.
    JOURNAL OF PATHOLOGY, 2023, 261 : S9 - S9
  • [45] Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy
    Mou, Exian
    Ji, Juan
    Liu, Shiwei
    Shu, Lan
    Zou, Liqun
    Li, Zhuoxuan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [46] Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer
    Maddox, Adam L.
    Brehove, Matthew S.
    Eliato, Kiarash R.
    Saftics, Andras
    Romano, Eugenia
    Press, Michael F.
    Mortimer, Joanne
    Jones, Veronica
    Schmolze, Daniel
    Seewaldt, Victoria L.
    Jovanovic-Talisman, Tijana
    CANCERS, 2022, 14 (11)
  • [47] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    MODERN PATHOLOGY, 2019, 32
  • [48] ERVMER34 sensitizes the response of HER2 positive breast cancer to neoadjuvant therapy
    Chi, Y.
    Ji, W.
    Xiu, B.
    Zhang, Q.
    Wu, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [49] Intra-tumor heterogeneity as a predictor of therapy response in HER2 positive breast cancer
    Rye, I. H.
    Helland, A.
    Saetersdal, A.
    Naume, B.
    Almendro, V.
    Polyak, K.
    Boressen-Dale, A-L
    Russnes, H. G.
    CANCER RESEARCH, 2012, 72
  • [50] Predictive Value of HER2 Fluorescence In Situ Hybridization (FISH) Result in HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Suo, Aili
    Zhang, Chao
    Shi, Quiying
    Wei, Zhimin
    Li, Zaibo
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
12345